Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol

INTRODUCTION: Chimeric antigen receptor (CAR) T cells spark hope for patients with CD19+ B cell neoplasia, including relapsed or refractory (r/r) acute lymphoblastic leukaemia (ALL) or r/r non-Hodgkin’s lymphoma (NHL). Published studies have mostly used second-generation CARs with 4-1BB or CD28 as c...

Descripción completa

Detalles Bibliográficos
Autores principales: Schubert, Maria-Luisa, Schmitt, Anita, Sellner, Leopold, Neuber, Brigitte, Kunz, Joachim, Wuchter, Patrick, Kunz, Alexander, Gern, Ulrike, Michels, Birgit, Hofmann, Susanne, Hückelhoven-Krauss, Angela, Kulozik, Andreas, Ho, Anthony D., Müller-Tidow, Carsten, Dreger, Peter, Schmitt, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Haematology (Incl Blood Transfusion)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530404/
https://www.ncbi.nlm.nih.gov/pubmed/31110096
http://dx.doi.org/10.1136/bmjopen-2018-026644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530404/
https://www.ncbi.nlm.nih.gov/pubmed/31110096
http://dx.doi.org/10.1136/bmjopen-2018-026644

Ejemplares similares